Back to Screener

Apollomics Inc. Warrant (APLMW)

Price$0.01
Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-64.39%
Price vs S&P 500 (4W)-28.84%
VGM Score24.35

All Metrics

Price vs S&P 500 (YTD)-57.45%
10-Day Avg Trading Volume0.07M
3-Month Avg Trading Volume0.02M
52-Week Price Return-46.92%
52-Week High$0.03
26-Week Price Return-48.46%
13-Week Price Return-48.46%
3-Month Return Std Dev154.57%
Price vs S&P 500 (52W)-77.44%
Year-to-Date Return-48.46%
5-Day Price Return5.51%
Month-to-Date Return-19.76%
Price vs S&P 500 (13W)-58.21%
Beta1.28x
52-Week Low$0.01
mGradeD
vgmGradeD
Show chart for

Industry Peers — Pharmaceuticals(550)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
APLMWApollomics Inc. Warrant
D$0.01
LLYEli Lilly & Co.DBB$1082.20
JNJJohnson & JohnsonCCC$223.51
ABBVABBVIE INC.DCC$212.93
MRKMerck & Co., Inc.CCC$115.17
NVSNovartis AGCCC$145.68
AZNAstraZeneca PLCDBC$179.71
NVONovo-Nordisk A/SBBC$44.07
ABTAbbott LaboratoriesCCD$87.78
PFEPfizer Inc.BCC$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary SharesCCC$34.64

About

Apollomics Inc is a clinical-stage biopharmaceutical company developing oncology therapies that target molecular pathways and enhance immune response. Its lead candidates include vebreltinib, a c-Met inhibitor for non-small cell lung cancer and other c-Met-altered tumors, and uproleselan, an E-Selectin antagonist designed for use with chemotherapy in acute myeloid leukemia.